# US 2008/0269233 A1 · Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0269233 A1
- Document ID: US20080269233A1
- Status: Published application
- Kind: A1
- Application number: 11/997,824
- Filed: 2006-07-26
- Published: 2008-10-30
- Earliest claimed: 2006-07-26
- Inventors: Mark David Andrews; Alan Daniel Brown; David Sebastien; Mark Ian Lansdell
- Web page: https://patentgrep.com/patent/US20080269233A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/10: of the bladder
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/10: for impotence
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/10: Anti-acne agents
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a class of compounds of general formula (I) and the salts, hydrates, solvates, polymorphs and prodrugs wherein n, R6, R7 and R10 are as defined herein and especially to MCR4 agonist compounds of formula (I), to their use in medicine, particularly in the treatment of sexual dysfunction and obesity, to intermediates useful in their synthesis and to compositions containing them.

## Claims

### Claim 1

A compound of formula (I):
wherein:
n is 1 or 2;
R6 is selected from H, C1-C6alkyl, C3-C8cycloalkyl, aryl, heterocyclyl, heteroaryl, C(O)C1-C6alkyl, CO2C1-C6alkyl, wherein each of said moieties is optionally substituted with one or more substituents independently selected from halo, CN, OH, ═O, NH2, NHCH3, N(CH3)2, C1-C4alkyl and C1-C4alkoxy;
R7 is selected from pyridinyl and phenyl, wherein said pyridinyl or said phenyl is optionally substituted by 1-3 groups independently selected from halo, CN, CF3, OCF3, OC1-C4alkyl and C1-C4alkyl;
R10 is a substituted piperidine group of formula (II):
wherein
R1 and R4 are each independently selected from H, C1-C4alkyl, OH, O(C1-C4alkyl), CH2OCH3 and NR8R9;
R2 is selected from H, OH, OC1-C4alkyl and NR8R9;
R3 is selected from aryl or heteroaryl, wherein said moieties are optionally substituted with one or more substituents independently selected from halo, CN, CF3, OCF3, O(C1-C4alkyl), and C1-C4alkyl;
R5 is selected from H and C1-C4alkyl;
R8 is selected from H and C1-C4alkyl, wherein said C1-C4alkyl is optionally substituted with OH or OCH3;
R9 is selected from H, C1-C4alkyl, SO2C1-C4alkyl, C(O)C1-C4alkyl;
wherein aryl means a six or ten membered aromatic hydrocarbon ring which is optionally fused to another six or ten membered aromatic hydrocarbon ring;
wherein heteroaryl means a 5 or 6 membered aromatic ring, containing from 1 to 4 heteroatoms, said heteroatoms each independently selected from O, S and N, wherein said aromatic ring may be optionally fused to an aryl or second, non-fused, aromatic heterocyclic ring;
wherein heterocyclyl means a 4 to 7 membered saturated or partially saturated ring, containing from 1 to 2 heteroatoms each independently selected from O, S and N;
wherein halo means Cl, F, Br or I;
and pharmaceutically acceptable salts, hydrate, solvates, polymorphs and prodrugs thereof, with the provisos that:
R1, R4 and R5 are not all simultaneously H;
when R1 is methyl and R4 is H, then R5 is not methyl;
when R4 is methyl and R5 is H, then R1 is not methyl; and
when R5 is methyl and R4 is H, then R1 is not methyl.

### Claim 2 (depends on 1)

A compound, salt, hydrate, solvate, polymorph or prodrug according to claim 1 wherein:
n is 1;
R1 is selected from H, methyl, OH, OCH3, OC2H5 and NR8R9;
R2 is selected from H, OH, and OC1-C4alkyl;
R3 is selected from aryl or heteroaryl, wherein said moieties are optionally substituted with one or more substituents independently selected from halo, CN, CF3, OCF3, OCH3, OC2H5, methyl and ethyl;
R4 is selected from H, methyl, OH, OCH3, OC2H5 and NR8R9;
R5 is selected from H, methyl and ethyl;
R6 is selected from C1-C6alkyl, C3-C8cycloalkyl, heterocyclyl, heteroaryl, C(O)C1-C6alkyl, CO2C1-C6alkyl, wherein each of said moieties are optionally substituted with one or more substituents independently selected from halo, CN, OH, ═O, C1-C4alkyl and C1-C4alkoxy;
R7 is selected from pyridinyl and phenyl, wherein said pyridinyl or said phenyl is substituted by 1-3 groups independently selected from halo, CN, CF3, OCF3, OCH3 and methyl;
R8 is selected from H, methyl, ethyl and propyl wherein said alkyl groups is optionally substituted with OH or OCH3;
and R9 is selected from H, C1-C4alkyl and SO2C1-C4alkyl.

### Claim 3 (depends on 1)

A compound, salt, hydrate, solvate, polymorph or prodrug according to claim 1 wherein R6 is selected from:

### Claim 4 (depends on 1)

A compound, salt, hydrate, solvate, polymorph or prodrug according to claim 1 wherein R7 is selected from:

### Claim 5 (depends on 1)

A compound, salt, hydrate, solvate, polymorph or prodrug according to claim 1 wherein R10 is selected from:

### Claim 6 (depends on 1, 2, 3, 4, 5)

A compound, salt, hydrate, solvate, polymorph or prodrug according to any of claims 1 to 5 for use as a medicament.

### Claim 7 (depends on 1, 2, 3, 4, 5)

A compound, salt, hydrate, solvate, polymorph or prodrug according to any of claims 1 to 5 for use as a medicament for the treatment of a condition which would benefit from the agonism of a MCR4 receptor.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The use of a compound, salt, hydrate, solvate, polymorph or prodrug according to any of claims 1 to 5 in the preparation of a medicament for the treatment of a condition which would benefit from the agonism of a MCR4 receptor.

### Claim 9 (depends on 8)

The use according to claim 8 wherein the condition is a sexual dysfunction.

### Claim 10 (depends on 9)

The use according to claim 9 wherein the sexual dysfunction is male erectile dysfunction.

### Claim 11 (depends on 9)

The use according to claim 9 wherein the sexual dysfunction is female sexual arousal disorder.

### Claim 12 (depends on 8)

The use according to claim 8 wherein the condition is obesity.

### Claim 13 (depends on 1, 2, 3, 4, 5)

A method of treating a condition which would benefit from agonism of a MCR4 receptor which comprises administering to a patient in need thereof an effective amount of a compound, salt, hydrate, solvate, polymorph or prodrug according to any one of claims 1 to 5.

### Claim 14 (depends on 1, 2, 3, 4, 5)

A pharmaceutical composition comprising a compound, salt, hydrate, solvate, polymorph or prodrug according to any one of claims 1 to 5, and a pharmaceutically acceptable diluent or carrier.
